Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Alterity Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.35.
Current Consensus is
The current consensus among 0 contributing investment analysts is to n/a stock in Alterity Therapeutics. This N/A consensus rating has held steady for over two years.
Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.